{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where docket_id = \"FDA-2014-D-2175\" sorted by posted_date descending", "rows": [["FDA-2014-D-2175-0041", "FDA", "FDA-2014-D-2175", "Recommendations for Assessment of Blood Donor Eligibility, Donor Deferral and Blood Product Management in Response to Ebola Virus Guidance for Industry", "Other", "Guidance", "2017-01-10T05:00:00Z", 2017, 1, "2017-01-10T05:00:00Z", null, "2024-11-12T06:17:52Z", null, 1, 0, "090000648245701d"], ["FDA-2014-D-2175-0040", "FDA", "FDA-2014-D-2175", "Recommendations for Assessment of Blood Donor Eligibility, Donor Deferral and Blood Product Management in Response to Ebola Virus; Guidance for Industry; Availability", "Notice", "Notice of Availability", "2017-01-10T05:00:00Z", 2017, 1, "2017-01-10T05:00:00Z", null, "2017-01-10T14:40:59Z", "2017-00200", 0, 0, "0900006482456a50"], ["FDA-2014-D-2175-0022", "FDA", "FDA-2014-D-2175", "Reference -19 Molecular Evidence of Sexual Transmission of Ebola Virus    re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:45:46Z", null, 0, 0, "0900006481d88bb3"], ["FDA-2014-D-2175-0024", "FDA", "FDA-2014-D-2175", "Reference  21 - Risk Factors for Zaire Ebolavirus  re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:46:39Z", null, 0, 0, "0900006481d88c02"], ["FDA-2014-D-2175-0007", "FDA", "FDA-2014-D-2175", "Reference 4 - Horowitz-1992-Solvent detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:39:29Z", null, 0, 0, "0900006481d83cbc"], ["FDA-2014-D-2175-0013", "FDA", "FDA-2014-D-2175", "Reference 10 - Ebola Virus Disease in West Africa  -The First 9 Months\nof the Epidemic and Forward Projections    re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:41:43Z", null, 0, 0, "0900006481d8405a"], ["FDA-2014-D-2175-0021", "FDA", "FDA-2014-D-2175", "Reference 18 - CDC-Possible Sexual on of Ebola Virus\u2013Liberia re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:45:23Z", null, 0, 0, "0900006481d84b63"], ["FDA-2014-D-2175-0008", "FDA", "FDA-2014-D-2175", "Reference 5 - Robustness of Solvent/Detergent Treatment of Plasma Derivatives: A Data collection from Plasma Protein Therapeutics Association member companies re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:39:55Z", null, 0, 0, "0900006481d83cbd"], ["FDA-2014-D-2175-0020", "FDA", "FDA-2014-D-2175", "Reference  -17 Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors  Preliminary Report re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:44:52Z", null, 0, 0, "0900006481d88baf"], ["FDA-2014-D-2175-0023", "FDA", "FDA-2014-D-2175", "Reference - 20 Leroy_Human Asymptomatic Ebola Infection re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:46:13Z", null, 0, 0, "0900006481d88bfd"], ["FDA-2014-D-2175-0027", "FDA", "FDA-2014-D-2175", "Reference 24 - Correlates of Immunity to Filovirus Infection re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:47:55Z", null, 0, 0, "0900006481d89163"], ["FDA-2014-D-2175-0026", "FDA", "FDA-2014-D-2175", "Reference 23 - Ebola Virus Can Be Effectively Neutralized by Antibody\nProduced in Natural Human Infection re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:47:27Z", null, 0, 0, "0900006481d8915f"], ["FDA-2014-D-2175-0032", "FDA", "FDA-2014-D-2175", "Reference 29 - Ebola haemorrhagic fever in Zaire, 1976  re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:49:54Z", null, 0, 0, "0900006481d89352"], ["FDA-2014-D-2175-0005", "FDA", "FDA-2014-D-2175", "Reference 2 - Towner-2008-Newly Discovered Ebola virus Associated with\nHemorrhagic Fever Outbreak in Uganda re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:38:28Z", null, 0, 0, "0900006481d83cac"], ["FDA-2014-D-2175-0009", "FDA", "FDA-2014-D-2175", "Reference 6 - Solvent-Detergent Filtered (S/D-F) Fresh Frozen Plasma and\nCryoprecipitate Minipools Prepared in a Newly Designed Integral Disposable Processing Bag System re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:40:20Z", null, 0, 0, "0900006481d8411c"], ["FDA-2014-D-2175-0031", "FDA", "FDA-2014-D-2175", "Reference 28 -Ebola Hemorrhagic Fever: Evaluation of Passive Immunotherapy in Nonhuman Primates re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:49:30Z", null, 0, 0, "0900006481d898d3"], ["FDA-2014-D-2175-0017", "FDA", "FDA-2014-D-2175", "Reference 14 - Persistence and Genetic Stability of Ebola Virus during the Outbreak in Kikwit, Democratic Republic of the Congo, 1995 re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:43:24Z", null, 0, 0, "0900006481d84255"], ["FDA-2014-D-2175-0006", "FDA", "FDA-2014-D-2175", "Reference 3 Mitchell-1984-Physicochemical Inactivation of Lassa, Ebola, and Marburg Viruses and Effect on Clinical Laboratory Analyses  re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:38:57Z", null, 0, 0, "0900006481d83cbb"], ["FDA-2014-D-2175-0012", "FDA", "FDA-2014-D-2175", "Reference 9 - Incubation Period of Ebola Hemorrhagic Virus Subtype Zaire re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:41:22Z", null, 0, 0, "0900006481d84124"], ["FDA-2014-D-2175-0028", "FDA", "FDA-2014-D-2175", "Reference 25 -Successful Treatment of Ebola Virus-Infected Cynomolgus Macaques with Monoclonal Antibodies re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:48:19Z", null, 0, 0, "0900006481d89218"], ["FDA-2014-D-2175-0033", "FDA", "FDA-2014-D-2175", "Reference 30 - A Case of Ebola Virus Infection    re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:50:22Z", null, 0, 0, "0900006481d89356"], ["FDA-2014-D-2175-0004", "FDA", "FDA-2014-D-2175", "Reference 1 - Feldmann-2003-Ebola virus from discovery to vaccine re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:38:07Z", null, 0, 0, "0900006481d83c18"], ["FDA-2014-D-2175-0034", "FDA", "FDA-2014-D-2175", "Reference 31- Treatment of Ebola Hemorrhagic Fever with Blood Transfusions from Convalescent Patients re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:50:44Z", null, 0, 0, "0900006481d8937b"], ["FDA-2014-D-2175-0015", "FDA", "FDA-2014-D-2175", "Reference 12 - Persistence of Ebola Virus in Ocular Fluid during Convalescence re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:42:36Z", null, 0, 0, "0900006481d8424f"], ["FDA-2014-D-2175-0030", "FDA", "FDA-2014-D-2175", "Reference 27 - Postexposure antibody prophylaxis protects nonhuman\nprimates from filovirus disease re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:49:06Z", null, 0, 0, "0900006481d898cc"], ["FDA-2014-D-2175-0025", "FDA", "FDA-2014-D-2175", "Reference 22 -Efficacy of Immune Plasma in Treatment of Argentine re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:47:02Z", null, 0, 0, "0900006481d8915d"], ["FDA-2014-D-2175-0029", "FDA", "FDA-2014-D-2175", "Reference 26 - Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:48:41Z", null, 0, 0, "0900006481d8921b"], ["FDA-2014-D-2175-0014", "FDA", "FDA-2014-D-2175", "Reference 11 - On The Quarantine Period For Ebola Virus re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:42:16Z", null, 0, 0, "0900006481d8405e"], ["FDA-2014-D-2175-0016", "FDA", "FDA-2014-D-2175", "Reference 13 - Assessment of the Risk of Ebola Virus Transmission from Bodily Fluids and Fomites re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:43:00Z", null, 0, 0, "0900006481d84252"], ["FDA-2014-D-2175-0003", "FDA", "FDA-2014-D-2175", "Reference List re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:37:31Z", null, 0, 0, "0900006481d83c17"], ["FDA-2014-D-2175-0011", "FDA", "FDA-2014-D-2175", "Reference 8 - Inactivation of Viruses in Platelet Concentrates by Photochemical Treatment with Amotosalen and Long-Wavelength Ultraviolet Light re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:41:02Z", null, 0, 0, "0900006481d84122"], ["FDA-2014-D-2175-0018", "FDA", "FDA-2014-D-2175", "Reference 15 - Clinical, Virologic, and Immunologic Follow-Up of Convalescent Ebola Hemorrhagic Fever Patients and Their Household Contacts, Kikwit, Democratic Republic of the Congo re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:43:49Z", null, 0, 0, "0900006481d84333"], ["FDA-2014-D-2175-0019", "FDA", "FDA-2014-D-2175", "Reference 16 - Unexpected Ebola Virus in a Tertiary Setting: Clinical and Epidemiologic Aspects re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:44:17Z", null, 0, 0, "0900006481d844c9"], ["FDA-2014-D-2175-0010", "FDA", "FDA-2014-D-2175", "Reference  7 - Photochemical Treatment of Plasma with Amotosalen and Longwavelength Ultraviolet Light Inactivates Pathogens while Retaining\nCoagulation Function re Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2015-12-07T05:00:00Z", 2015, 12, null, null, "2015-12-07T14:40:40Z", null, 0, 0, "0900006481d8411e"], ["FDA-2014-D-2175-0002", "FDA", "FDA-2014-D-2175", "Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry", "Other", "Guidance", "2015-12-03T05:00:00Z", 2015, 12, "2015-12-03T05:00:00Z", null, "2024-11-11T21:15:27Z", null, 1, 0, "0900006481d83b25"], ["FDA-2014-D-2175-0001", "FDA", "FDA-2014-D-2175", "Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus; Draft Guidance for Industry; Availability", "Notice", "Notice of Availability", "2015-12-03T05:00:00Z", 2015, 12, "2015-12-03T05:00:00Z", "2015-03-03T04:59:59Z", "2015-12-03T15:01:08Z", "2015-30589", 0, 0, "0900006481d82bc1"]], "truncated": false, "filtered_table_rows_count": 36, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"docket_id\" = :p0 order by posted_date desc limit 101", "params": {"p0": "FDA-2014-D-2175"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2014-D-2175", "results": [{"value": "FDA", "label": "FDA", "count": 36, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2014-D-2175&agency_id=FDA", "selected": false}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2014-D-2175", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 32, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2014-D-2175&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Notice", "label": "Notice", "count": 2, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2014-D-2175&document_type=Notice", "selected": false}, {"value": "Other", "label": "Other", "count": 2, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2014-D-2175&document_type=Other", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2014-D-2175", "results": [{"value": 2015, "label": 2015, "count": 34, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2014-D-2175&posted_year=2015", "selected": false}, {"value": 2017, "label": 2017, "count": 2, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2014-D-2175&posted_year=2017", "selected": false}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2014-D-2175&_facet=subtype"}, {"name": "posted_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2014-D-2175&_facet=posted_date"}, {"name": "posted_month", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2014-D-2175&_facet=posted_month"}, {"name": "comment_start_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2014-D-2175&_facet=comment_start_date"}, {"name": "open_for_comment", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2014-D-2175&_facet=open_for_comment"}, {"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2014-D-2175&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2014-D-2175&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2014-D-2175&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2014-D-2175&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 7.608476094901562, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}